MOXAVAL-CL 625 combines Amoxicillin, a broad-spectrum penicillin antibiotic, with Potassium
Clavulanate, a β-lactamase inhibitor, to enhance the effectiveness of Amoxicillin against
bacteria that produce β-lactamase enzymes. This combination therapy provides potent
antibacterial action against a variety of infections, ensuring optimal therapeutic outcomes.
Key Benefits:
● Provides broad-spectrum coverage against both gram-positive and gram-negative
bacteria
● Overcomes bacterial resistance caused by β-lactamase-producing organisms
● Effective for treating respiratory, urinary, and skin infections
● Convenient dosage formulation for improved patient compliance
● Well-tolerated with a favorable safety profile
Indications:
● Respiratory tract infections (e.g., pneumonia, bronchitis, sinusitis)
● Urinary tract infections (e.g., cystitis, pyelonephritis)
● Skin and soft tissue infections (e.g., cellulitis, abscesses)
● Otitis media, tonsillitis, and other ENT infections